Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.